Strong growth momentum driving Cadila Healthcare

Cadila Healthcare continues moving from strength to strength as concerns over its Gujarat facility dissipate. The stock saw a highs of Rs 1,760 in November and had corrected to a closing low of Rs 1,463 last month. It has since regained, to Rs 1,700 levels.

....

In this backdrop, analysts expect Cadila to post strong growth. For instance, those at Ambit Capital estimate a compounded growth of 21.5 per cent in sales and 36 per cent in net profit over FY14-17, implying an operating earnings' margin expansion of 447 basis points in this period, largely led by niche opportunities in the US and Hydrochloroquine (Plaquenil). The approvals anticipated in niche segments in the US are in transdermals, nasal sprays and controlled release products.

https://www.business-standard.com/article/markets/strong-growth-momentum-driving-cadila-healthcare-115032500144_1.html